Financial PerformanceThe company reported FY3Q25 revenues of C$6.2M and a net loss of C$0.66 per diluted share, compared to the consensus estimated revenues of C$7.0M and a net loss of C$0.08 per share.
Market ConditionsIPA shares have declined this year with a dip in the overall market and uncertainties related to potential drug tariffs and government R&D spending.
Operational RisksRisks include commercial, execution, legal and IP, and competition.